Clinical Trial Update: Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Phase 2 trial comparing six doses of CP-690,550 (tofacitinib) plus methotrexate to placebo plus methotrexate in rheumatoid arthritis; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CP-690,550 (tofacitinib) (tofacitinib)
• METHOTREXATE (METHOTREXATE)

Snippet

Sponsor: Pfizer | Conditions: Arthritis, Rheumatoid | Phase 2 | Status: COMPLETED | Results posted: 2013-01-08